Objective. The aim of this study was to examine the influence of chemokines and lipids on cardiac function in patients with active and inactive JDM and matched controls.
Introduction JDM is a rare systemic CTD in childhood. It is characterized by inflammation and vasculopathy of small vessels in skeletal muscles, skin and internal organs [1, 2] . The use of corticosteroids has substantially decreased the mortality of JDM, from >30% to <2% [3, 4] . Nevertheless, 6090% of JDM patients still develop organ damage within the skin, muscle, skeleton, lungs and cardiovascular and gastrointestinal systems [1, 5, 6] . Inflammation is a key factor in the pathogenesis of both cardiovascular [7, 8] and rheumatic diseases, including DM [9, 10] . Monocyte chemoattractant protein 1 (MCP-1) plays an essential role in the development of atherosclerotic heart disease in humans [11] . A recent meta-analysis on RA showed that anti-TNF-a treatment reduced the risk of cardiovascular events [12] , and in 23 RA patients, IL-1 antagonists improved left ventricular (LV) function [13] . This suggests that pro-inflammatory cytokines are involved in the development of cardiovascular complications in RA. Decreased cholesterol levels in RA were observed in a controlled study of 93 patients in 1991 [14] . Indeed, increased atherosclerotic burden in rheumatic diseases has been well documented [15] , which may seem like a paradox [16] . Patients with rheumatic diseases have increased susceptibility to atherosclerotic disease despite cholesterol levels in the normal range. Impaired lipid metabolism in JDM has also been reported [17, 18] . Lipodystrophy is associated with impaired lipid metabolism and is a known complication of the disease, reported in 1740% of cases [19, 20] . An uncontrolled study showed elevated triglycerides and insulin resistance in 50% of 20 JDM patients with a median disease duration of 2.5 years (range 013) [17] . We have recently shown systolic and diastolic cardiac dysfunction [21, 22] and higher serum levels of eotaxin and MCP-1 [23] in JDM after long-term follow-up. However, no studies have previously addressed the impact of circulating lipid and cytokine levels on cardiac function in patients with myositis. In this study we assessed lipid levels in patients compared with sex-and age-matched controls and in patients with active vs inactive disease. Since the mechanism of cardiac affection in JDM remains unknown, we wanted to study the significance of interactions between cytokines, lipid parameters and inflammation in the development of cardiac dysfunction.
Patients and methods

Patients and controls
Inclusion criteria provide a probable or definitive diagnosis of DM according to Bohan and Peter [24] , including disease onset before 18 years, a minimum disease duration of 24 months and age 56 years at inclusion. We identified a retrospective inception cohort of 66 JDM patients in Norway diagnosed between January 1970 and June 2006, previously described in detail [1] . Of 66 patients, 4 were deceased and 3 did not want to participate. Sexand age-matched controls were randomly drawn from the National Population Register. Exclusion criteria for controls were mobility problems, inflammatory rheumatic disease, other autoimmune conditions treated with immunosuppressive agents and heart or lung disease (except for mild asthma). After cytokine analyses, statistical calculations to detect outliers were performed and five pairs were excluded (see statistical analysis). The data presented are based on the remaining 54 patients and 54 controls.
Informed 2009 . Disease onset was defined as the time of the first muscle or skin symptom clearly related to JDM (by chart review) and disease duration was defined as the time from disease onset to examination. Inactive disease was defined by the proposed PRINTO criteria of 2012, with three of the following: manual muscle testing 578 (080, eight muscle groups), physician global assessment of overall disease activity using a visual analogue scale (phyGloVAS) 40.2, Childhood Myositis Assessment Scale (CMAS) 548 and creatine kinase 4150 U/l [25, 26] .
Cytokine and lipid analyses
Serum concentrations of 26 cytokines were quantified using the Bio-Plex protein array system (Bio-Rad, Hercules, CA, USA), based on xMAP technology (Luminex, Austin, TX, USA). The Luminex analyses were performed according to the manufacturer's protocol, with minor modifications, including selection of a high-sensitivity standard curve to optimize measurements of nonseptic concentrations of cytokines, described in detail earlier [23, 27] . For the present study we selected the three cytokines previously found to be elevated in JDM patients compared with controls, the chemokines eotaxin (CCL11), MCP-1 (CCL2) and interferon-inducible protein 10 (IP-10, CXCL10) [23] . High eotaxin and MCP-1 levels were defined as serum concentrations greater than the mean + 2 S.D. of the values in the matched controls (>236 and >48 pg/ml, respectively).
Total cholesterol (TC), high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides and lipoprotein A were analysed and HDL:LDL and TC:HDL ratios [28] were calculated. The serum samples were collected from non-fasting patients and controls.
Echocardiography Two-dimensional M-mode and Doppler echocardiography was performed by an experienced investigator (I.S.) with a Vivid 7 ultrasound scanner (GE Vingmed Ultrasound, Horten, Norway) [29, 30] . A minimum of three cardiac cycles were recorded, analysed and averaged. The echocardiographic data were analysed blinded to clinical information and to patient/control identity (T.S.).
Mitral annulus (MA) displacement was assessed by anatomical M-mode in the lateral and septal position using the four-chamber apical view. LV length was assessed as the distance from the endocardial border of the apex to the midportion of the MA plane. Long-axis strain was calculated as MA displacement as a percentage of LV end-diastolic length, as previously described in detail [21] . Low long-axis strain is associated with systolic dysfunction.
Colour-coded tissue Doppler was performed in 53 patients and 53 controls, with a frame rate of $180. We used sample volumes from MA in the lateral and septal position in four-chamber view and two corresponding positions in two-chamber view. Early diastolic transmitral flow (E) and early diastolic tissue velocity (e 0 ). Both high E/e 0 [31] and www.rheumatology.oxfordjournals.org low e 0 are commonly used parameters reflecting LV diastolic dysfunction [32] . In our calculations we used e 0 alone, thus when using the term diastolic function we are referring to this.
Statistical analysis
Paired and unpaired sample t-tests were used in comparisons between patients and matched controls and between patient groups, respectively, for normally distributed continuous variables. Two-tailed tests were used for all calculations except for comparisons where a priori patients based on the literature were likely not to have lower values than controls. P-values <0.05 were considered significant. Correlations were determined by Spearman's correlation coefficient (r). Associations between cardiovascular parameters (dependent variables) and eotaxin, MCP-1, TC and active/inactive disease state (independent variables) were controlled for male gender and disease duration in a linear regression model with forward deletion of the variables. SPSS version 20.0 (SPSS, Chicago, IL, USA) was used for statistical analyses.
To detect outliers, the Mahalanobis distance from the cytokine level of each individual to its respective group mean were calculated. Bonferroni corrected P-values were obtained based on an approximation of the Mahalanobis distance to a chi-squared distribution with the number of cytokines as degrees of freedom. One patient and four controls had samples with a P-value <0.001; these five and their matched control or patient were therefore removed from the data set, resulting in 54 patientcontrol pairs that were used in the present study.
Results
Characteristics, cardiovascular parameters and chemokine levels in patients and controls As previously shown [23] , MCP-1, IP-10 and eotaxin were elevated in patients compared with controls (P = 0.006, P = 0.026 and P = 0.039, respectively), but no differences in cytokine level were seen between JDM active and inactive patients.
Patients with JDM had lower long-axis strain and e 0 than matched controls, whereas no differences were seen in blood pressure or ejection fraction (Table 1) . HDL, LDL and TC were all lower, while the TC:HDL ratio and triglycerides were higher in patients than in controls. Lipoprotein A and the HDL:LDL ratio as well as BMI were comparable in patients and controls. Between JDM active and JDM inactive patients, none of these parameters differed. Lipodystrophy was clinically present in 10 patients (18%), 7 JDM active and 3 JDM inactive High serum levels of MCP-1 were found more often in patients than in controls [n = 13 (24%) vs n = 2 (4%), P = 0.02]. Seven patients (13%) and three controls (6%) had high eotaxin levels (P = 0.42), whereas four patients (7%) and one control (2%) had both high eotaxin and MCP-1 levels (P = 0.57).
Associations between chemokines and cardiac parameters in patients with active and inactive disease and in controls
In JDM active but not JDM inactive patients, correlations were present between serum levels of eotaxin and MCP-1 and both long-axis strain and e 0 ( Table 2 , Fig. 1 ). Also, correlations in JDM active but not JDM inactive patients were seen between eotaxin and blood pressure. MCP-1 correlated with diastolic blood pressure in JDM active patients only. Neither eotaxin nor MCP-1 correlated with left ventricular ejection fraction (LVEF). Serum levels of IP-10 did not correlate with any cardiac parameters (data not shown). In controls, no correlations between chemokines and long-axis strain, e 0 , blood pressure or LVEF were seen.
FIG. 1 Correlations between chemokines and cardiac function in JDM
Correlations between serum levels of eotaxin and monocyte chemoattractant protein 1 (MCP-1) and systolic (long-axis strain) (A and B) and diastolic function (e 0 : early diastolic tissue velocity) (C and D) in 54 patients with JDM. r: Spearman's correlation coefficient. P < 0.001. BMI showed a negative correlation with systolic and diastolic function in patients (r = À0.51 and r = À0.51, P < 0.001) that was stronger than in controls (r = À0.27, P = 0.05 and r = À0.36, P = 0.008). Correlations were seen between BMI and eotaxin and MCP-1 in patients (r = 0.39, P = 0.004 and r = 0.29, P = 0.04) but not in controls (r = 0.07, P = 0.60 and r = 0.06, P = 0.65).
In a multiple linear regression model in the patients, an association between MCP-1 and e 0 was observed (standardized b = À0.38, P = 0.001) with contributions from the control measures (male gender, standardized b = À0.19, P = 0.05; disease duration, standardized b = À0.46, P < 0.001; R 2 final model = 65%). This was not seen for long-axis strain or blood pressure. For eotaxin in similar models, no associations were found for either e 0 , long-axis strain nor blood pressure (data not shown). Associations between cardiac parameters, lipids and chemokines in patients with active and inactive disease and in controls TC levels were comparable in JDM active and JDM inactive patients (Table 1) . However, in JDM active patients, correlations between TC and long-axis strain, e 0 , blood pressure and chemokines were present; in JDM inactive patients, none of these correlations were seen (Table 3 , Fig. 2 ). For the TC:HDL ratio, a similar pattern was seen: correlations were present with e 0 and chemokines in JDM active patients only. For the TC:HDL ratio and long-axis strain, a correlation was seen both in JDM active and JDM inactive patients. In the controls, only weak or no correlations between both TC and TC:HDL ratio and cardiac parameters or the chemokines were seen. We have previously addressed the relationship between medication and cardiac function [21, 22] , cytokine expression [23] and disease activity [26] . In the present study we found no correlations between lipid profile and cumulative prednisolone dose, use of MTX, AZA or cyclosporin.
Discussion
In JDM patients after medium to long-term follow-up, we have previously shown cardiac dysfunction [21, 22] and increased levels of eotaxin and MCP-1 [23] , all associated with organ damage and disease activity. In the present study, serum levels of eotaxin and MCP-1 correlated with cardiac systolic and diastolic dysfunction as well as with elevated blood pressure in those with active disease. Similarly, total cholesterol level and the TC:HDL ratio correlated with the same cardiovascular parameters as well as with eotaxin and MCP-1 in patients with active disease only. Although our study cannot establish a causal relationship, the findings could indicate that chemokines and cholesterol are involved in cardiac impairment in JDM. To our knowledge, in myositis, no study addressing the role of cytokines, lipids and inflammation in cardiac dysfunction has been performed.
Strengths of our study include the representativeness of our inception cohort, which we believe covers most of the JDM cases in Norway diagnosed from 1970 to 2006; it has been described earlier in detail [1] . Also, sex-and agematched controls were randomly drawn for the National Population Register.
Long-axis strain expresses the MA plane movement towards the apex or longitudinal myocardial shortening (cardiac systolic function). e 0 is the peak early myocardial relaxation velocity and reflects myocardial stiffness and relaxation ability (cardiac diastolic function). Some authors see impaired systolic and diastolic function as two separate pathways to a failing heart [33] . However, others consider this as a continuum of cardiac damage, as systolic heart failure is associated with impaired diastolic parameters and abnormal longitudinal systolic function can be seen in patients with predominantly diastolic heart failure [34] . Our data show intercorrelation between long-axis strain and e 0 [21], and both are associated with the same cytokines; this tends to support the latter view.
MCP-1 is the cytokine perhaps most tightly linked to myocardial inflammation and fibrosis [35] . It is involved in the mechanism of atherosclerosis development [11] and predicts cardiovascular events in patients with acute coronary syndrome [36] . Studies have also shown association between MCP-1 and autoimmune myocarditis [37] . Twenty-four patients with histology-proven myocarditis had higher levels of MCP-1 than controls, in particular those with a fatal outcome [38] . MCP-1 is the most important agonist to chemokine receptor 2 (CCR2) and is a chemoattractant for mononuclear cells [39] . It is responsible for directed migration of monocytes to inflamed tissue. In two series from the early 1980s, 20 and 16 adult patients with myositis were autopsied and cardiac inflammation with mononuclear cell infiltration resembling myocarditis was found [40, 41] . For children and adolescents, such documentation does not exist, but it is reasonable to believe that a similar myocardial inflammation occurs in JDM as well.
Eotaxin acts chemotactically through CCR3 and partly CCR2 and mediates eosinophils [39] and mast cells [42] . Eotaxin is closely related to MCP-1. Although far less studied, associations with fibrosis in bleomycin-injured lung tissue in mice [43] and in transplanted hearts in rats [44] have been shown.
In the present study, correlations between cardiac function and eotaxin and MCP-1 were only seen in the patients, and particularly those in an active disease state. Accordingly, cardiac dysfunction was more pronounced in patients with high vs low levels of eotaxin and MCP-1. In the multiple linear regression analysis, high MCP-1 was associated with low e 0 in patients. Patients with high eotaxin had lower long-axis strain than those with normal levels. MCP-1 might be linked mostly to diastolic function, while eotaxin is linked to systolic function. Given the inflammatory nature of the disease, our long-term data with impaired diastolic or systolic parameters may reflect a sustained low-grade myocardial inflammation. This is supported by the observation that eotaxin and MCP-1 are linked to cardiac dysfunction in JDM active patients only. Inflammation could induce myocardial remodelling, subsequently leading to fibrosis and increased stiffness of the heart. As eotaxin and MCP-1 both are agonists to CCR2 and inflammatory mediators in JDM, one could speculate that receptor blockade might modify the disease course, and perhaps organ damage, including cardiac affection. However, when tested clinically on synovial inflammation in 32 RA patients, this treatment had no effect [45] .
Previous studies have shown impaired lipid metabolism in JDM: in eight patients a median 29 years after disease www.rheumatology.oxfordjournals.org onset, HDL cholesterol was lower than in controls [18] . Recently another controlled study showed lower HDL but comparable TC in 25 JDM patients assessed 0.511 years after disease onset [46] . In our study the patients had lower HDL, LDL and TC levels than the controls. This is also observed in RA, and treatment of the active disease can typically result in an increase in cholesterol levels [16] . However, the relationship between rheumatic diseases, inflammation and lipid profile appears to be complex [47] . In RA, increased cardiovascular burden is due to atherosclerotic disease [48] , this has also been shown for adult DM [49] . A link between atherosclerosis and cardiac dysfunction in long-term JDM is not yet shown; however, in our study, atherogenic risk factors were present. In a meta-analysis, the TC:HDL ratio proved to be superior to other lipid parameters, including TC level and HDL:LDL ratio, in predicting ischaemic heart disease [28] . Our JDM patients had a higher TC:HDL ratio than controls, indicating an unfavourable lipid profile. Also, 18% of the patients had lipodystrophy, a prevalence in concordance with previous reports [19, 20] . In line with the literature [17], impaired lipid parameters were present in patients with lipodystrophy. However, the association with disease outcomes was not investigated due to low numbers.
It is possible that our JDM patients are still too young to have developed overt, detectable atherosclerotic heart disease. Our findings might reflect an early stage in atherosclerotic development or the atherosclerosis may already be present as small vessel disease.
Interestingly, in JDM active patients, substantial correlations were seen between both TC levels and the TC:HDL ratio and all cardiac parameters; correlations that were present neither in JDM inactive patients nor in controls. JDM active patients might be more sensitive to pathological myocardial remodelling due to chronic inflammation. Hence the threshold of harmful cholesterol levels could be lowered in these individuals compared with those with inactive disease or the general population, supported by our observations. Seemingly at risk of cardiovascular complications, it is possible that JDM active patients would benefit from more aggressive cholesterol-lowering treatment, as has been discussed in RA patients [47] . If statins are introduced, muscle enzymes and symptoms should be closely monitored to avoid worsening of the myositis or rhabdomyolysis.
A controlled study with long-term (median 29 years) follow-up showed increased blood pressure in JDM [18]. We did not detect any such difference. However, in our data blood pressure correlated in particular with eotaxin. Also, increased blood pressure was linked to higher TC in JDM active patients but not in JDM inactive patients. The pattern seen for blood pressure is similar to that seen for cardiac function; the same pathophysiological responses suggested in the myocardium could also cause arterial stiffness and increased peripheral resistance.
A limitation of our analyses is serum samples from nonfasting subjects. Since food intake particularly affects triglycerides, we did not include this in the correlation analyses.
In conclusion, in 54 JDM patients seen a median 16.8 years after disease onset, elevated blood pressure and cardiac dysfunction was associated with increased levels of eotaxin and MCP-1, in particular in those with active disease. Lower cholesterol levels were observed in JDM patients than in controls. Nevertheless, in JDM active patients, impaired cardiovascular parameters and pro-inflammatory chemokines correlated with increasing levels of cholesterol, unlike in JDM inactive patients and controls. Therefore it is possible that eotaxin and MCP-1 play a role as inflammatory mediators of cardiac dysfunction in JDM. Furthermore, they may also increase vulnerability to cholesterol in the active disease state. Prospective follow-up studies could clarify whether targeted receptor blockers of the chemokines and the use of statins can prevent cardiovascular complications in JDM. For clinicians to stratify patients at particular cardiovascular risk, the PRINTO criteria for clinically inactive disease might be useful.
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. Eotaxin and MCP-1 are associated with cardiac dysfunction in JDM. . In active disease state of JDM, cholesterol in the upper normal range is associated with cardiac dysfunction. . Eotaxin and MCP-1 may increase vulnerability to cholesterol in active disease state of JDM.
